Woo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan, Phyu P Aung, Denái R Milton, Mario L Marques-Piubelli, Courtney Hudgens, Debora Ledesma, Kelly Nelson, Doina Ivan, Miao Zhang, Carlos A Torres-Cabala, Matthew Campbell, Omar Alhalabi, Victor G Prieto, Ignacio I Wistuba, Bita Esmaeli, Jonathan L Curry
BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4 that is used to treat urothelial carcinoma. Nectin-4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin-4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. METHODS: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody...
January 10, 2024: Journal of Cutaneous Pathology